机构：[1]Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[2]Department of Urology, Institute of Urology, Laboratory of Reconstructive Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[3]West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[4]West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China.
We conducted a meta-analysis to assess the efficacy and safety of dose-dense chemotherapy in the treatment of patients with urothelial carcinoma. A systematic search was conducted in PubMed, Medline, Embase, Web of Science and Cochrane Collaboration's Central register of controlled trials (CENTRAL) for relevant articles. Data was obtained from 10 trials with a total of 1093 patients. The pooled pathologic complete response (pCR) was 27.8% in the ten studies with a full cohort of 684 patients who received dose-dense methotrexate, vinblastine, adriamycin and cisplatin (dd-MVAC). In the controlled trials, although the difference was not significant, the pCR rate in the dd-MVAC group has a trend of increase (odds ratio (OR) 1.52; 95% confidence interval (CI) 0.78-2.98, P = 0.22) compared with classic MVAC group. A significant improvement of overall survival (OS) (hazard ratio (HR) 0.77, 95% CI 0.61-0.97, p = 0.03) was also observed. Hematologic toxicities were the most frequent grade ≥ 3 toxicities including neutropenia/febrile neutropenia (17.5%), anemia (9.4%) and thrombocytopenia (6.1%). Compared with the classic MVAC group, dd-MVAC was associated with significantly decreased risks of all-grade adverse events (AEs) such as anemia (OR 0.457, 95% CI 0.249-0.840, p = 0.012), febrile neutropenia (OR 0.398 95% CI 0.233-0.681, p = 0.001), and neutropenia (OR 0.373, 95% CI 0.201-0.691, p = 0.002). In conclusion, dose-dense chemotherapy was effective and tolerable in patients with urothelial carcinoma, which could be considered as a reasonable therapeutic option.
基金：
Grant No. 2014K158 from the Administration of
Traditional Chinese Medicine of Sichuan, Grant No.
2017SZ0048 from Science and Technology Administration,
Sichuan Province, Grant No. 2014SZ0031 from Science
and Technology Administration, Sichuan Province, Grant
No. 16PJ298 from Health and Family Planning Commission
of Sichuan Province. Grant No.2015-RK00-00233-ZF from
Science and Technology Administration, Chengdu.Grant
No. 2014K158 from the Administration of Traditional
Chinese Medicine of Sichuan, Grant No. 2017SZ0048
from Science and Technology Administration, Sichuan
Province, Grant No. 2014SZ0031 from Science and
Technology Administration, Sichuan Province, Grant No.
16PJ298 from Health and Family Planning Commission of
Sichuan Province. Grant No.2015-RK00-00233-ZF from
Science and Technology Administration, Chengdu.Grant
No. 2014K158 from the Administration of Traditional
Chinese Medicine of Sichuan, Grant No. 2017SZ0048 from
Science and Technology Administration, Sichuan Province,
Grant No. 2014SZ0031 from Science and Technology
Administration, Sichuan Province, Grant No. 16PJ298
from Health and Family Planning Commission of Sichuan
Province. Grant No.2015-RK00-00233-ZF from Science
and Technology Administration, Chengdu
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区肿瘤学3 区细胞生物学
最新[2023]版：
无
第一作者：
第一作者机构：[1]Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhu Chenjing,Liu Jiaming,Zhang Jing,et al.Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.[J].Oncotarget.2017,8(41):71117-71127.doi:10.18632/oncotarget.16759.
APA：
Zhu Chenjing,Liu Jiaming,Zhang Jing,Li Qingfang,Lian Qisi...&Ma Xuelei.(2017).Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma..Oncotarget,8,(41)
MLA：
Zhu Chenjing,et al."Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.".Oncotarget 8..41(2017):71117-71127
